The randomised, managed, single-blind trial of the Oxford vaccine ran between 23 April and 21 Might 2020 and involveed 1,077 wholesome adults aged 18–55 years with no historical past of COVID-19.
Contributors acquired both the experimental COVID-19 vaccine or a licensed meningococcal conjugate vaccine (MenACWY); 113 contributors had been additionally requested to take paracetamol earlier than and for twenty-four hours after their vaccination to reduce antagonistic reactions.
Ten contributors assigned to a non-randomised, unblinded prime-boost group acquired a two-dose schedule of the COVID-19 vaccine, with the booster vaccine administered 28 days after the primary dose.
The COVID-19 vaccine was discovered to have a suitable security profile and there have been no critical antagonistic occasions.
Native and systemic reactions had been extra frequent within the COVID-19 group, though many had been lowered by use of prophylactic paracetamol, together with ache, feeling feverish, chills, muscle ache, headache, and malaise.
Fatigue and headache had been probably the most generally reported reactions: fatigue was reported by 70% of contributors given the COVID-19 vaccine with out paracetamol (71% of these with paracetamol), versus 48% of these given the MenACWY vaccine with out paracetamol; headache was reported by 68% of the COVID-19 group with out paracetamol (61% with paracetamol), versus 41% of contributors within the MenACWY group with out paracetamol.